OpenEvidence, a Miami-based AI-powered medical search platform founded in 2022 by Daniel Nadler, has rapidly gained traction among U.S. physicians, with nearly two-thirds of doctors using its chatbot to process over 42 million prompts monthly. The tool helps clinicians navigate medical journals and clinical guidelines to support diagnosis and treatment decisions, relying on an ad-supported model that generated $100 million in ad buys by the end of 2025 and is projected to reach $400–$500 million in ad revenue by 2026. The startup’s aggressive growth has drawn nearly $1 billion in funding over 18 months, including a $250 million round in September 2025 that valued the company at $15 billion. Despite praise from physicians for reducing workloads, the platform faces increasing competition from tech giants like OpenAI and Anthropic, as well as scrutiny over the accuracy of its outputs as doctors become more reliant on its recommendations. OpenEvidence’s success highlights the slow adoption of generative AI in traditional medical software, exemplified by Wolters Kluwer’s delayed AI integration into its UpToDate platform in October 2025—nearly two years after OpenEvidence launched.